Description of Clinical Expertise

Lawrence N. Shulman, MD, is the Associate Director for Special Projects of the Abramson Cancer Center at the University of Pennsylvania, and Director of the Center for Global Cancer Medicine.

Dr. Shulman is immediate past Chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former Chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer’s Quality Integration Committee. In this regard, Dr. Shulman serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda, Lesotho, and Haiti, programs for which he plays a seminal leadership role. He sits on the Vice Chancellor’s Advisory Council for Rwanda’s University for Global Health Equity. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership.

Dr. Shulman is a former member of ASCO’s International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization’s review and revision of their Essential Medicines for Cancer from 2014-2017.

He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

Description of Other Expertise

Dr Shulman has a long history of development and implementation of information technology solutions to improve the efficiency and safety of cancer care delivery. He continues to develop tools to improve data capture in electronic health records (EHRs) and to utilize those and patient reported outcomes to understand treatment and outcomes of real world patients in the US.

Description of Research Expertise

His research includes innovations in cancer care delivery, both in the US and in resource constrained settings, including Rwanda, Lesotho, Botswana and Haiti.